Using a genetic marker on thyroid biopsy samples
Part of Hormones & metabolism clinical trials.
This study looks at thyroid biopsy samples that were 'suspicious' for cancer. It tests a special marker (BRAF V600E) to see if it can help tell whether the suspicious cells are actually cancer, which may improve diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a fine needle aspiration biopsy (FNAC) of your thyroid.
- The biopsy result was 'suspicious for papillary thyroid cancer'.
- You had surgery to remove your thyroid, and the tissue was checked in the lab.
- Your original biopsy slides are still available for review.
- Your slides are in good condition and not blocked by blood or other material.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
This study compares genetic testing results from a small needle biopsy to those from the surgically removed thyroid tissue. It aims to see if the biopsy alone can accurately predict the cancer's genetics, which could help guide treatment decisions.
This study is looking at how certain substances in the blood (called biomarkers) can help doctors understand and treat advanced thyroid cancer. It is for people who are about to start their first systemic therapy (medication that works throughout the body) for advanced thyroid cancer, and who have already had a genetic test on their tumor.
This study looks at whether a genetic test called GuidePx® helps doctors plan surgery for thyroid cancer. It may help avoid unnecessary surgeries by guiding the best treatment for each person.
This study looks at blood and urine samples from people newly diagnosed with papillary thyroid cancer or suspected follicular thyroid tumors. The goal is to find biomarkers that help predict risk and monitor the disease after treatment.
This trial studies the genetic “mutations” in papillary thyroid cancer tumors using tumor tissue. The goal is to better describe tumor genetic patterns, which may help researchers understand the disease.
Hear when a new Suspicious for Papillary Thyroid Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.